

Press release - regulated information

Information on the total number of voting rights and shares

Ghent, BELGIUM – 5 July 2021 – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Biotalys NV (the "Company") (Euronext - BTLS) publishes the following information following the realisation of a capital increase by issuance of new shares:

- Share capital: €79,953,137.91
- Total number of securities carrying voting rights: 30,020,387 (all ordinary shares)
- Total number of voting rights (= denominator): 30,020,387 (all relating to ordinary shares)
- Number of rights to subscribe securities carrying voting rights not yet issued:
 - 2,787,072 "ESOP Warrants", entitling their holders to subscribe for a total number of 2,787,072 profit certificates which will, if and when issued, automatically convert into a total number of maximum 1,393,536 securities carrying voting rights (all ordinary shares)
 - 1 "Over-allotment Warrant", entitling its holder to subscribe for a total number of maximum 949,999 securities carrying voting rights (all ordinary shares)

- ENDS -

For further information, please contact:

Biotalys

Toon Musschoot, Strategic Communications Manager

T: +32 (0)9 274 54 00

E: <u>Toon.Musschoot@Biotalys.com</u>

For media enquiries, please contact:

Consilium Strategic Communications

Amber Fennell, Chris Gardner, Chris Welsh

T: +44 (0)203 709 5700

E: Biotalys@consilium-comms.com

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for more sustainable and safer food. Based on its novel AGROBODY™ technology platform, Biotalys aims to develop a strong and diverse pipeline of effective products with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and was listed on Euronext Brussels on 2 July 2021. The

company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.